AMPK Promotes Aberrant PGC1β Expression To Support Human Colon Tumor Cell Survival

REFERENCES

• Stephen Andrew G, Esposito D, Bagni Rachel K, McCormick F. 2014. Dragging Ras back in the ring. Cancer Cell 25:272–281. http://dx.doi.org/10.1016/j.ccr.2014.02.017.
   PubMedGoogle Scholar
• Dhillon AS, Hagan S, Rath O, Kolch W. 2007. MAP kinase signalling pathways in cancer. Oncogene 26:3279–3290. http://dx.doi.org/10.1038/sj.onc.1210421.
   PubMed Web of Science ®Google Scholar
• Roberts PJ, Der CJ. 2007. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 26:3291–3310. http://dx.doi.org/10.1038/sj.onc.1210422.
   PubMed Web of Science ®Google Scholar
• Nguyen A, Burack WR, Stock JL, Kortum R, Chaika OV, Afkarian M, Muller WJ, Murphy KM, Morrison DK, Lewis RE, McNeish J, Shaw AS. 2002. Kinase suppressor of Ras (KSR) is a scaffold which facilitates mitogen-activated protein kinase activation in vivo. Mol Cell Biol 22:3035–3045. http://dx.doi.org/10.1128/MCB.22.9.3035-3045.2002.
   PubMed Web of Science ®Google Scholar
• Kortum RL, Lewis RE. 2004. The molecular scaffold KSR1 regulates the proliferative and oncogenic potential of cells. Mol Cell Biol 24:4407–4416. http://dx.doi.org/10.1128/MCB.24.10.4407-4416.2004.
   PubMed Web of Science ®Google Scholar
• Fisher KW, Das B, Kortum RL, Chaika OV, Lewis RE. 2011. Kinase suppressor of ras 1 (KSR1) regulates PGC1α and estrogen-related receptor alpha to promote oncogenic Ras-dependent anchorage-independent growth. Mol Cell Biol 31:2453–2461. http://dx.doi.org/10.1128/MCB.05255-11.
   PubMed Web of Science ®Google Scholar
• Xing HR, Cordon-Cardo C, Deng X, Tong W, Campodonico L, Fuks Z, Kolesnick R. 2003. Pharmacologic inactivation of kinase suppressor of ras-1 abrogates Ras-mediated pancreatic cancer. Nat Med 9:1266–1268.
   PubMed Web of Science ®Google Scholar
• Llobet D, Eritja N, Domingo M, Bergada L, Mirantes C, Santacana M, Pallares J, Macia A, Yeramian A, Encinas M, Moreno-Bueno G, Palacios J, Lewis RE, Matias-Guiu X, Dolcet X. 2011. KSR1 is overexpressed in endometrial carcinoma and regulates proliferation and TRAIL-induced apoptosis by modulating FLIP levels. Am J Pathol 178:1529–1543. http://dx.doi.org/10.1016/j.ajpath.2010.12.041.
   PubMedGoogle Scholar
• Potts MB, Kim HS, Fisher KW, Hu Y, Carrasco YP, Bulut GB, Ou YH, Herrera-Herrera ML, Cubillos F, Mendiratta S, Xiao G, Hofree M, Ideker T, Xie Y, Huang LJ, Lewis RE, MacMillan JB, White MA. 2013. Using functional signature ontology (FUSION) to identify mechanisms of action for natural products. Sci Signal 6:ra90. http://dx.doi.org/10.1126/scisignal.2004657.
   PubMed Web of Science ®Google Scholar
• Roig AI, Eskiocak U, Hight SK, Kim SB, Delgado O, Souza RF, Spechler SJ, Wright WE, Shay JW. 2010. Immortalized epithelial cells derived from human colon biopsies express stem cell markers and differentiate in vitro. Gastroenterology 138:1012–1021.e1–5. http://dx.doi.org/10.1053/j.gastro.2009.11.052.
   PubMed Web of Science ®Google Scholar
• Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP. 2005. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 102:15545–15550. http://dx.doi.org/10.1073/pnas.0506580102.
   PubMed Web of Science ®Google Scholar
• Kawada M, Fukazawa H, Mizuno S, Uehara Y. 1997. Inhibition of anchorage-independent growth of ras-transformed cells on polyHEMA surface by antisense oligodeoxynucleotides directed against K-ras. Biochem Biophys Res Commun 231:735–737. http://dx.doi.org/10.1006/bbrc.1997.6179.
   PubMedGoogle Scholar
• Xu L-H, Yang X, Bradham CA, Brenner DA, Baldwin AS, Craven RJ, Cance WG. 2000. The focal adhesion kinase suppresses transformation-associated, anchorage-independent apoptosis in human breast cancer cells. J Biol Chem 275:30597–30604. http://dx.doi.org/10.1074/jbc.M910027199.
   PubMed Web of Science ®Google Scholar
• Costanzo-Garvey DL, Pfluger PT, Dougherty MK, Stock JL, Boehm M, Chaika O, Fernandez MR, Fisher K, Kortum RL, Hong EG, Jun JY, Ko HJ, Schreiner A, Volle DJ, Treece T, Swift AL, Winer M, Chen D, Wu M, Leon LR, Shaw AS, McNeish J, Kim JK, Morrison DK, Tschop MH, Lewis RE. 2009. KSR2 is an essential regulator of AMP kinase, energy expenditure, and insulin sensitivity. Cell Metab 10:366–378. http://dx.doi.org/10.1016/j.cmet.2009.09.010.
   PubMed Web of Science ®Google Scholar
• Gao G, Fernandez CS, Stapleton D, Auster AS, Widmer J, Dyck JRB, Kemp BE, Witters LA. 1996. Non-catalytic beta- and gamma-subunit isoforms of the 5′-AMP-activated protein kinase. J Biol Chem 271:8675–8681. http://dx.doi.org/10.1074/jbc.271.15.8675.
   PubMedGoogle Scholar
• Woods A, Cheung PCF, Smith FC, Davison MD, Scott J, Beri RK, Carling D. 1996. Characterization of AMP-activated protein kinase and subunits. J Biol Chem 271:10282–10290. http://dx.doi.org/10.1074/jbc.271.17.10282.
   PubMed Web of Science ®Google Scholar
• Adams J, Chen ZP, Van Denderen BJ, Morton CJ, Parker MW, Witters LA, Stapleton D, Kemp BE. 2004. Intrasteric control of AMPK via the γ1 subunit AMP allosteric regulatory site. Protein Sci 13:155–165. http://dx.doi.org/10.1110/ps.03340004.
   PubMed Web of Science ®Google Scholar
• Villena JA, Kralli A. 2008. ERRα: a metabolic function for the oldest orphan. Trends Endocrinol Metab 19:269–276. http://dx.doi.org/10.1016/j.tem.2008.07.005.
   PubMedGoogle Scholar
• Spiegelman BM. 2007. Transcriptional control of mitochondrial energy metabolism through the PGC1 coactivators. Novartis Found Symp 287:60–63. http://dx.doi.org/10.1002/9780470725207.ch5.
   PubMedGoogle Scholar
• Cheung PC, Salt IP, Davies SP, Hardie DG, Carling D. 2000. Characterization of AMP-activated protein kinase gamma-subunit isoforms and their role in AMP binding. Biochem J 346:659–669. http://dx.doi.org/10.1042/bj3460659.
   PubMed Web of Science ®Google Scholar
• Jeon SM, Hay N. 2012. The dark face of AMPK as an essential tumor promoter. Cell Logist 2:197–202. http://dx.doi.org/10.4161/cl.22651.
   PubMedGoogle Scholar
• Liang J, Mills GB. 2013. AMPK: a contextual oncogene or tumor suppressor? Cancer Res 73:2929–2935. http://dx.doi.org/10.1158/0008-5472.CAN-12-3876.
   PubMed Web of Science ®Google Scholar
• Faubert B, Boily G, Izreig S, Griss T, Samborska B, Dong Z, Dupuy F, Chambers C, Fuerth BJ, Viollet B, Mamer OA, Avizonis D, DeBerardinis RJ, Siegel PM, Jones RG. 2013. AMPK is a negative regulator of the Warburg effect and suppresses tumor growth in vivo. Cell Metab 17:113–124. http://dx.doi.org/10.1016/j.cmet.2012.12.001.
   PubMed Web of Science ®Google Scholar
• Hemminki A, Markie D, Tomlinson I, Avizienyte E, Roth S, Loukola A, Bignell G, Warren W, Aminoff M, Hoglund P, Jarvinen H, Kristo P, Pelin K, Ridanpaa M, Salovaara R, Toro T, Bodmer W, Olschwang S, Olsen AS, Stratton MR, de la Chapelle A, Aaltonen LA. 1998. A serine/threonine kinase gene defective in Peutz-Jeghers syndrome. Nature 391:184–187. http://dx.doi.org/10.1038/34432.
   PubMed Web of Science ®Google Scholar
• Jenne DE, Reimann H, Nezu J, Friedel W, Loff S, Jeschke R, Muller O, Back W, Zimmer M. 1998. Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase. Nat Genet 18:38–43. http://dx.doi.org/10.1038/ng0198-38.
   PubMed Web of Science ®Google Scholar
• Lizcano JM, Goransson O, Toth R, Deak M, Morrice NA, Boudeau J, Hawley SA, Udd L, Makela TP, Hardie DG, Alessi DR. 2004. LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR-1. EMBO J 23:833–843. http://dx.doi.org/10.1038/sj.emboj.7600110.
   PubMed Web of Science ®Google Scholar
• DeCensi A, Puntoni M, Goodwin P, Cazzaniga M, Gennari A, Bonanni B, Gandini S. 2010. Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res 3:1451–1461. http://dx.doi.org/10.1158/1940-6207.CAPR-10-0157.
   PubMed Web of Science ®Google Scholar
• Andrzejewski S, Gravel S-P, Pollak M, St-Pierre J. 2014. Metformin directly acts on mitochondria to alter cellular bioenergetics. Cancer Metab 2:12. http://dx.doi.org/10.1186/2049-3002-2-12.
   PubMedGoogle Scholar
• Miller RA, Chu Q, Xie J, Foretz M, Viollet B, Birnbaum MJ. 2013. Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP. Nature 494:256–260. http://dx.doi.org/10.1038/nature11808.
   PubMed Web of Science ®Google Scholar
• Shen CH, Yuan P, Perez-Lorenzo R, Zhang Y, Lee SX, Ou Y, Asara JM, Cantley LC, Zheng B. 2013. Phosphorylation of BRAF by AMPK impairs BRAF-KSR1 association and cell proliferation. Mol Cell 52:161–172. http://dx.doi.org/10.1016/j.molcel.2013.08.044.
   PubMed Web of Science ®Google Scholar
• Jones RG, Plas DR, Kubek S, Buzzai M, Mu J, Xu Y, Birnbaum MJ, Thompson CB. 2005. AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol Cell 18:283–293. http://dx.doi.org/10.1016/j.molcel.2005.03.027.
   PubMed Web of Science ®Google Scholar
• Inoki K, Zhu T, Guan KL. 2003. TSC2 mediates cellular energy response to control cell growth and survival. Cell 115:577–590. http://dx.doi.org/10.1016/S0092-8674(03)00929-2.
   PubMed Web of Science ®Google Scholar
• Gwinn DM, Shackelford DB, Egan DF, Mihaylova MM, Mery A, Vasquez DS, Turk BE, Shaw RJ. 2008. AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell 30:214–226. http://dx.doi.org/10.1016/j.molcel.2008.03.003.
   PubMed Web of Science ®Google Scholar
• Wang C, Rajput S, Watabe K, Liao DF, Cao D. 2010. Acetyl-CoA carboxylase-a as a novel target for cancer therapy. Front Biosci (Schol Ed) 2:515–526.
   PubMedGoogle Scholar
• Hardie DG. 2007. AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. Nat Rev Mol Cell Biol 8:774–785. http://dx.doi.org/10.1038/nrm2249.
   PubMed Web of Science ®Google Scholar
• Laderoute KR, Amin K, Calaoagan JM, Knapp M, Le T, Orduna J, Foretz M, Viollet B. 2006. 5′-AMP-activated protein kinase (AMPK) is induced by low-oxygen and glucose deprivation conditions found in solid-tumor microenvironments. Mol Cell Biol 26:5336–5347. http://dx.doi.org/10.1128/MCB.00166-06.
   PubMed Web of Science ®Google Scholar
• Ng TL, Leprivier G, Robertson MD, Chow C, Martin MJ, Laderoute KR, Davicioni E, Triche TJ, Sorensen PH. 2012. The AMPK stress response pathway mediates anoikis resistance through inhibition of mTOR and suppression of protein synthesis. Cell Death Differ 19:501–510. http://dx.doi.org/10.1038/cdd.2011.119.
   PubMed Web of Science ®Google Scholar
• Fernandez MR, Henry MD, Lewis RE. 2012. Kinase suppressor of Ras 2 (KSR2) regulates tumor cell transformation via AMPK. Mol Cell Biol 32:3718–3731. http://dx.doi.org/10.1128/MCB.06754-11.
   PubMed Web of Science ®Google Scholar
• Liu X, Chhipa RR, Pooya S, Wortman M, Yachyshin S, Chow LM, Kumar A, Zhou X, Sun Y, Quinn B, McPherson C, Warnick RE, Kendler A, Giri S, Poels J, Norga K, Viollet B, Grabowski GA, Dasgupta B. 2014. Discrete mechanisms of mTOR and cell cycle regulation by AMPK agonists independent of AMPK. Proc Natl Acad Sci U S A 111:E435–E444. http://dx.doi.org/10.1073/pnas.1311121111.
   PubMed Web of Science ®Google Scholar
• Jeon SM, Chandel NS, Hay N. 2012. AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress. Nature 485:661–665. http://dx.doi.org/10.1038/nature11066.
   PubMed Web of Science ®Google Scholar
• Svensson RU, Shaw RJ. 2012. Cancer metabolism: Tumour friend or foe. Nature 485:590–591. http://dx.doi.org/10.1038/485590a.
   PubMed Web of Science ®Google Scholar
• Viollet B, Athea Y, Mounier R, Guigas B, Zarrinpashneh E, Horman S, Lantier L, Hebrard S, Devin-Leclerc J, Beauloye C, Foretz M, Andreelli F, Ventura-Clapier R, Bertrand L. 2009. AMPK: lessons from transgenic and knockout animals. Front Biosci 14:19–44.
   PubMed Web of Science ®Google Scholar
• Ros S, Santos CR, Moco S, Baenke F, Kelly G, Howell M, Zamboni N, Schulze A. 2012. Functional metabolic screen identifies 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 as an important regulator of prostate cancer cell survival. Cancer Discov 2:328–343. http://dx.doi.org/10.1158/2159-8290.CD-11-0234.
   PubMed Web of Science ®Google Scholar
• Banko MR, Allen JJ, Schaffer BE, Wilker EW, Tsou P, White JL, Villén J, Wang B, Kim SR, Sakamoto K, Gygi SP, Cantley LC, Yaffe MB, Shokat KM, Brunet A. 2011. Chemical genetic screen for AMPKα2 substrates uncovers a network of proteins involved in mitosis. Mol Cell 44:878–892. http://dx.doi.org/10.1016/j.molcel.2011.11.005.
   PubMedGoogle Scholar
• Chang CY, Kazmin D, Jasper JS, Kunder R, Zuercher WJ, McDonnell DP. 2011. The metabolic regulator ERRα, a downstream target of HER2/IGF-1R, as a therapeutic target in breast cancer. Cancer Cell 20:500–510. http://dx.doi.org/10.1016/j.ccr.2011.08.023.
   PubMed Web of Science ®Google Scholar
• Ariazi EA, Clark GM, Mertz JE. 2002. Estrogen-related receptor alpha and estrogen-related receptor gamma associate with unfavorable and favorable biomarkers, respectively, in human breast cancer. Cancer Res 62:6510–6518.
   PubMed Web of Science ®Google Scholar
• Wang L, Liu Q, Li F, Qiu J, Fan H, Ma H, Zhu Y, Wu L, Han X, Yang Z, Jiang H, Wei J, Xia H. 2013. Apoptosis induced by PGC-1β in breast cancer cells is mediated by the mTOR pathway. Oncol Rep 30:1631–1638. http://dx.doi.org/10.3892/or.2013.2628.
   PubMedGoogle Scholar
• Li Y, Li Y, Wedren S, Li G, Charn TH, Desai KV, Bonnard C, Czene K, Humphreys K, Darabi H, Einarsdottir K, Heikkinen T, Aittomaki K, Blomqvist C, Chia KS, Nevanlinna H, Hall P, Liu ET, Liu J. 2011. Genetic variation of ESR1 and its co-activator PPARGC1B is synergistic in augmenting the risk of estrogen receptor-positive breast cancer. Breast Cancer Res 13:R10. http://dx.doi.org/10.1186/bcr2817.
   PubMed Web of Science ®Google Scholar
• Eichner LJ, Perry MC, Dufour CR, Bertos N, Park M, St-Pierre J, Giguere V. 2010. miR-378(*) mediates metabolic shift in breast cancer cells via the PGC-1β/ERRγ transcriptional pathway. Cell Metab 12:352–361. http://dx.doi.org/10.1016/j.cmet.2010.09.002.
   PubMed Web of Science ®Google Scholar
• Deblois G, Chahrour G, Perry MC, Sylvain-Drolet G, Muller WJ, Giguere V. 2010. Transcriptional control of the ERBB2 amplicon by ERRα and PGC-1β promotes mammary gland tumorigenesis. Cancer Res 70:10277–10287. http://dx.doi.org/10.1158/0008-5472.CAN-10-2840.
   PubMedGoogle Scholar
• Jager S, Handschin C, St-Pierre J, Spiegelman BM. 2007. AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1α. Proc Natl Acad Sci U S A 104:12017–12022. http://dx.doi.org/10.1073/pnas.0705070104.
   PubMed Web of Science ®Google Scholar
• Fujita H, Yagishita N, Aratani S, Saito-Fujita T, Morota S, Yamano Y, Hansson MJ, Inazu M, Kokuba H, Sudo K, Sato E, Kawahara KI, Nakajima F, Hasegawa D, Higuchi I, Sato T, Araya N, Usui C, Nishioka K, Nakatani Y, Maruyama I, Usui M, Hara N, Uchino H, Elmer E, Nishioka K, Nakajima T. 2015. The E3 ligase synoviolin controls body weight and mitochondrial biogenesis through negative regulation of PGC-1β. EMBO J 34:1042–1055. http://dx.doi.org/10.15252/embj.201489897.
   PubMed Web of Science ®Google Scholar